We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
StemCells Inc. Advances Clinical Trial in AMD to Final Cohort
News

StemCells Inc. Advances Clinical Trial in AMD to Final Cohort

StemCells Inc. Advances Clinical Trial in AMD to Final Cohort
News

StemCells Inc. Advances Clinical Trial in AMD to Final Cohort

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "StemCells Inc. Advances Clinical Trial in AMD to Final Cohort"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

StemCells, Inc. has announced that it has transplanted the Company's proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD).

Each of the eight patients in this second cohort will receive a dose of 1 million stem cells into the most affected eye.

"We are very pleased with the rate of progress being made towards our goal of completing enrollment in this study by the end of this quarter," said Stephen Huhn, M.D., FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc.

Huhn continued, "We look forward to releasing the first interim results from this study next month and are planning to initiate a controlled Phase II proof-of-concept study later this year."

Advertisement